Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase

Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase

Breast cancer remains a leading cancer burden among women worldwide. Acquired resistance of cyclin-dependent kinase (CDK) 4/6 inhibitors occurs in almost all hormone receptor (HR)-positive subtype cases, comprising 70% of breast cancers, although CDK4/6 inhibitors combined with endocrine therapy are...

Full description

Bibliographic Details
Main Authors: Kamal Pandey, Nar Bahadur Katuwal, Nahee Park, Jin Hur, Young Bin Cho, Seung Ki Kim, Seung Ah Lee, Isaac Kim, Seung-Ryeol Lee, Yong Wha Moon
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
CDK4/6
hormone receptor-positive breast cancer
drug resistance
PLK1
Online Access:https://www.mdpi.com/2072-6694/14/1/210

Internet

https://www.mdpi.com/2072-6694/14/1/210

Similar Items